OCA improves event free survival – EASL 2022 – POSTER
Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
Patients treated with OCA in a trial setting demonstrated a statistically significant
and clinically meaningful 58% reduction in relative risk of hepatic decompensation, LT or death
compared to non-OCA treated patients in the GLOBAL PBC registry. Reduction in risk was
independent of cirrhosis. These results support the continued use of long-term OCA therapy to
optimize prognosis of patients with PBC. SEE POSTER.